About the Authors

Deirdre A. Collins

Contributed equally to this work with: Deirdre A. Collins, Anke Hoskins

dcollins@ichr.uwa.edu.au

Affiliation Telethon Institute for Child Health Research, Centre for Child Health Research, the University of Western Australia, Perth, Western Australia, Australia

Anke Hoskins

Contributed equally to this work with: Deirdre A. Collins, Anke Hoskins

Affiliation Telethon Institute for Child Health Research, Centre for Child Health Research, the University of Western Australia, Perth, Western Australia, Australia

Jacinta Bowman

Affiliation Division of Microbiology & Infectious Diseases, PathWest Laboratory Medicine WA, Perth, Western Australia, Australia

Jade Jones

Affiliation Division of Microbiology & Infectious Diseases, PathWest Laboratory Medicine WA, Perth, Western Australia, Australia

Natalie A. Stemberger

Affiliations Division of Microbiology & Infectious Diseases, PathWest Laboratory Medicine WA, Perth, Western Australia, Australia, Microbiology & Immunology, School of Pathology and Laboratory Medicine, the University of Western Australia, Perth, Western Australia, Australia

Peter C. Richmond

Affiliation School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia

Amanda J. Leach

Affiliation Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia

Deborah Lehmann

Affiliation Telethon Institute for Child Health Research, Centre for Child Health Research, the University of Western Australia, Perth, Western Australia, Australia

Competing Interests

AH and AL have received research funding and support to attend conferences from GlaxoSmithKline and Pfizer Australia. PR has been a member of vaccine advisory boards for Wyeth and CSL Ltd and has received institutional funding for investigator-initiated research from GlaxoSmithKline Biologicals and Merck and received travel support from Pfizer and Baxter to present study data at international meetings. DL has been a member of the GlaxoSmithKline Australia Pneumococcal-Haemophilus influenzae-Protein D conjugate vaccine (‘‘Phid-CV’’) Advisory Panel, has received support from Pfizer Australia and GlaxoSmithKline Australia to attend conferences, has received an honorarium from Merck Vaccines to give a seminar at their offices in Pennsylvania and to attend a conference, and is an investigator on an investigator-initiated research grant funded by Pfizer Australia. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. All other authors have indicated they have no conflicts of interest.

Author Contributions

Conceived and designed the experiments: AH AL DL. Performed the experiments: DC AH JB JJ NAS. Analyzed the data: DC AH. Wrote the manuscript: DC AH PR DL.